“Roughly 18% of patients on the highest dose of the drug stopped treatment due to side effects, compared with 4% of those in the placebo group. Eli Lilly said those dropout rates were “highly correlated” to patients’ starting body mass index and included discontinuations due to “perceived excessive weight loss.”
Among those with a BMI of 35 or higher who took highest dose, 12% stopped treatment. Schott said that number is closer to the dropout rates seen in trials on Eli Lilly’s weight loss drug Zepbound and Novo Nordisk’s obesity injection Wegovy.
In a separate note on Thursday, BMO’s Seigerman said discontinuation rates “appear to highlight the speed and strength of weight loss was excessive for some patients with lower BMI.” But he said, “all in results are impressive.””
Market Data 
Markets 
AI
